AMC Entertainment reports Q1 2026 results today with short sellers pressing hard into a stock that has already bounced 42% over the past month — a collision of aggressive bearish positioning and a sharp recent recovery.
Short interest has climbed steadily for two weeks. It now accounts for 18.1% of the free float, up nearly 10% week-on-week to approximately 92.9 million shares. The ORTEX short score has drifted higher to 69.1 — a reading that places the stock in roughly the 6th percentile of the universe on short score rank, meaning it is more heavily shorted than nearly all peers. Days to cover runs at 4.3, so any forced covering would take days to execute. The borrow market is not yet severely constrained — availability has eased from the fully-depleted levels seen in mid-to-late April, when borrow was completely used up on multiple days — but borrow costs, at 1.27%, have risen about 38% over the past month, a sign that demand for shorts has been increasing. Options traders, meanwhile, are leaning the other way: the put/call ratio has dropped to 0.17, well below its 20-day average and near the lowest level of the past year, suggesting the derivatives market has tilted decisively toward calls as the stock surged.
The bull case centres on the 2026 film slate and a structural margin recovery. Estimates point to EBITDA growing more than 50% this year as margins are projected to expand from roughly 8% toward 12% by 2027. Net leverage, while still elevated at 9.3x, is expected to trend toward 7x by year-end — progress that matters to a balance sheet carrying approximately $3.9 billion in net debt. Bears counter that the company still faces persistent headwinds: a projected adjusted EBITDA loss of $7 million for the period suggests operational pain has not yet turned the corner, and with net income expected around negative $177 million alongside negative operating cash flow, the debt load remains the dominant risk. Analyst sentiment has been consistently negative, with Citigroup maintaining a Sell and trimming its target repeatedly — most recently to $1.10 in late February. Macquarie and Roth Capital also cut targets to $1.50 at the same time, leaving the consensus mean target at $1.92 against a current price of $1.59. That implies modest upside on paper, but the direction of analyst revisions has been uniformly lower.
The institutional picture adds a layer of texture. BlackRock added more than 6.5 million shares in Q1, bringing its stake to nearly 6.9% of shares outstanding — a notable build into weakness. Vanguard added a smaller position in the same period. CEO Adam Aron also reported an increase of more than 1.2 million shares as of late February, a signal of conviction from inside the company. Those inflows sit alongside Citadel, which cut its position by approximately 3.5 million shares in the final quarter of last year.
The Q1 print will test whether the box office recovery story is real enough to justify the stock's recent 42% monthly surge — or whether the bears accumulating 18% of the float are pricing a more painful operating reality than the bulls are prepared to accept.
See the live data behind this article on ORTEX.
Open AMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
